Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-BNCT with NBB-001 and NBB-002 in recurrent head and neck malignancies
ChiCTR2600130508Phase 2Not yet recruiting
- Sponsor
- Xiamen Humanity Hospital
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of borofalan in Cervicofacial Cancer, sponsored by Xiamen Humanity Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
borofalan
03
Conditions
Cervicofacial Cancer
Beyond the preview
Go deeper on ChiCTR2600130508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130508.